scholarly journals PS166. ABO Blood Type is not Associated with Outcome after Vascular Surgery

2011 ◽  
Vol 53 (6) ◽  
pp. 73S
Author(s):  
Koen M. van de Luijtgaarden ◽  
Erik J. Bakker ◽  
Sanne E. Hoeks ◽  
Michiel T. Voute ◽  
Yvette R. van Gestel ◽  
...  
Keyword(s):  
Vascular Surgery ◽  
Blood Type ◽  
Abo Blood Type

scholarly journals ABO Blood Type Does Not Influence the Risk of Cardiovascular Complications and Mortality after Vascular Surgery

2013 ◽  
Vol 45 (3) ◽  
pp. 256-260 ◽  
Author(s):  
E.J. Bakker ◽  
T.M. Valentijn ◽  
S.E. Hoeks ◽  
K.M. van de Luijtgaarden ◽  
F.W. Leebeek ◽  
...  
Keyword(s):  
Vascular Surgery ◽  
Cardiovascular Complications ◽  
Blood Type ◽  
Abo Blood Type ◽  
Complications And Mortality

Abstract 125: Association Between Abo Blood Group, Von Willebrand Factor and Factor VIII in Patients Undergoing Vascular Surgery

2017 ◽  
Vol 37 (suppl_1) ◽  
Author(s):  
Francisco Ujueta ◽  
Michael A Nardi ◽  
Yu Guo ◽  
Adriana Perez ◽  
Maya Rubin ◽  
...  
Keyword(s):  
Vascular Surgery ◽  
Factor Viii ◽  
Von Willebrand Factor ◽  
Statistical Significance ◽  
Blood Groups ◽  
Blood Type ◽  
Abo Blood Groups ◽  
Abo Blood Type ◽  
Von Willebrand ◽  
Willebrand Factor

Background: ABO blood groups have been associated with functional effects on factor VIII (FVIII), von Willebrand factor (vWF) and incident atherothrombosis. This study sought to examine the association between ABO blood type, FVIII and vWF in patients undergoing vascular surgery. Method: This is a retrospective analysis of data from a cohort of 181 patients undergoing elective vascular surgery. ABO blood type, FVIII and vWF was measured before surgery. The primary end point was the occurrence of MACE (defined as myocardial necrosis, myocardial infarction, stroke or death) within 30-days after surgery. Multivariable logistic regression modeling was used to estimate odds of MACE. Results: The mean age was 71.6 ± 9.8 and 29% were female. Non-O blood type was present in 105 patients (70 A, 27 B, 8 AB) and type O in 76 patients. Non-O had higher FVIII (128.2 ± 44.7 vs 112.4 ± 42.4, P<0.001) and vWF (176.0 ± 54.0 vs 133.2 ± 41.0, P<0.001) than type O. Thirty day MACE occurred in 38 (21.0%) patients; 25% in non-O and 15.8% in type O (P=0.13). After adjustment for age, sex, race, prior coronary artery disease and heart failure, patients with non-O blood type (vs. O) had a higher incidence of 30-day MACE (odds ratio 2.1, 95% CI 0.9 to 5.1, P=0.08) although statistical significance was not reached. There was no significant association between FVIII and vWF and 30-day MACE. Conclusions: Non-O blood type was associated with higher levels of FVIII and vWF and a trend towards increased 30-day MACE in patients undergoing vascular surgery. Larger studies across of ABO blood groups and perioperative events in different types of surgeries are warranted.

scholarly journals Impact of ABO Blood Group Type on Risk of Venous Thromboembolism in Patients with Cancer

Blood ◽  
2021 ◽  
Vol 138 (Supplement 1) ◽  
pp. 2119-2119
Author(s):  
Cornelia Englisch ◽  
Florian Moik ◽  
Stephan Nopp ◽  
Markus Raderer ◽  
Ingrid Pabinger ◽  
...  
Keyword(s):  
Risk Factor ◽  
Blood Type ◽  
Thrombotic Risk ◽  
Patients With Cancer ◽  
Abo Blood Type ◽  
Tumor Types ◽  
Risk Of Cancer ◽  
Very High ◽  
Study Inclusion

Abstract Introduction: Venous thromboembolism (VTE) is common in patients with cancer. Non-O blood type is associated with higher levels of factor FVIII activity and von Willebrand factor compared to blood type O, and has been identified as a risk factor for VTE in the general population. However, the impact of ABO blood type on risk of cancer-associated VTE has not been clarified. Methods: To determine the influence of non-O blood type on risk of cancer-associated VTE, we utilized the dataset of the Vienna Cancer and Thrombosis Study (CATS), which is a single center, prospective observational cohort study including patients with newly diagnosed or recurrent cancer. Patients were followed for objectively diagnosed, independently adjudicated VTE for a maximum of 2 years. VTE was quantified in competing risk analysis, accounting for all-cause mortality as competing outcome event. A proportional sub-hazard regression model according to Fine & Gray was used for between-group comparisons. Based on the violation of the proportional sub-hazard assumption, we explored potential time-dependent effects of non-O blood type on VTE risk in a restricted cubic spline analysis, modeling differences in risk estimates over follow-up time. Further, time-restricted subdistribution hazard ratios (SHR) were obtained specifically for the &lt;3 months and ≥3 months follow-up intervals. In a subgroup analysis, differences in VTE risk according to ABO-blood type were analyzed for patients with very high thrombotic risk tumor types (pancreatic, gastric, glioblastoma), compared to the remainder of patients. Results: In total, 1,708 patients were included in our analysis (46% female, median age: 61 years [interquartile range, IQR: 52-68]). The most common tumor types were lung (19%), breast (16%), and brain (14%) cancer, with 32% of solid tumor patients having metastatic disease at study inclusion. Over a median follow-up of 24 months (IQR: 10-24), 151 patients were diagnosed with VTE (cumulative 2-year incidence: 9.2%, 95% confidence interval [CI]: 7.9-10.7) and 649 patients died (2-year mortality: 38%). Overall, blood type O was present in 38% of patients, A in 40%, B in 15%, and AB in 7%. The cumulative incidence of VTE at 3-, 6-, 12-, and 24-months for patients with blood type O was 3.8% (95% CI: 2.5-5.5), 5.7% (95% CI: 4.1-7.7), 7.0% (95% CI: 5.1-9.1), and 7.6% (95% CI: 5.7-9.9), compared to 3.4% (95% CI: 2.4-4.7), 6.5% (95% CI: 5.1-8.1), 8.4% (95% CI:6.8-10.2), and 10.2% (95% CI: 8.4-12.2) in patients with non-O blood type (Gray´s test: p=0.103, Figure 1). Upon visual inspection of cumulative incidence functions, a violation of the proportional sub-hazard assumption was suspected. In restricted cubic spline analysis, estimating hazard ratio (HR) for VTE of patients with non-O compared to O blood type, a time-varying effect of non-O blood type towards an increased VTE risk was observed (Figure 2). Based on that, time-restricted competing risk regression models were performed. During the first 3 months of follow-up, no differences in VTE risk were found (SHR for non-O vs. O blood type: 1.00, 95% CI: 0.60-1.67, p=0.992). Beyond the first 3-month follow-up, patients with non-O blood type had an increased VTE risk compared to patients with blood type O (SHR 1.79, 95%CI: 1.12-2.85, p=0.015). In a subgroup analysis, no association with VTE risk was found in patients with very high thrombotic risk tumor types (SHR 0.94, 95% CI: 0.55-1.61, p=0.824). In contrast, in patients with low/intermediate risk cancer, non-O blood type was associated with increased risk of VTE (SHR 1.73, 95% CI: 1.09-2.73, p=0.019). Conclusion: Non-O blood type was identified as a time dependent risk factor for cancer-associated VTE. In the first 3 months after study inclusion, characterized as the highest VTE risk period in our cancer cohort, no differences in VTE risk between blood types were found. Afterwards, beyond the first 3 months of follow-up, an increased VTE-risk in non-O blood types was observed, comparably in magnitude to the risk difference in the general non-cancer population. Further, an association of non-O blood type with VTE risk in patients with low/intermediate thrombotic risk cancers was observed, whereas no effect was present in those with very high-risk tumors. These findings indicate non-O blood type as a putative risk factor for VTE in patients with cancer in comparably low thrombotic risk scenarios. Figure 1 Figure 1. Disclosures Pabinger: Pfizer: Consultancy, Honoraria; Amgen: Consultancy, Honoraria; Novartis: Consultancy, Honoraria; Alexion: Consultancy, Honoraria; Daiichi Sanchyo: Consultancy, Honoraria; Takeda: Consultancy, Honoraria; Bayer: Consultancy, Honoraria; NovoNordisk: Consultancy, Research Funding; CSL Behring: Consultancy, Honoraria, Research Funding.

scholarly journals Body Mass Index and Its Association with Genetically Transmitted Traits

2020 ◽  
Vol 2020 ◽  
pp. 1-5
Author(s):  
Sultan Z. Alasmari ◽  
Nashwa Eisa ◽  
Saeed Mastour Alshahrani ◽  
Mohammad Mahtab Alam ◽  
Prasanna Rajagopalan ◽  
...  
Keyword(s):  
Body Mass Index ◽  
Body Mass ◽  
Female Students ◽  
Blood Type ◽  
Hair Color ◽  
Healthy Weight ◽  
Genetic Traits ◽  
Eye Color ◽  
Abo Blood Type ◽  
Chi Square Analysis

Background. Body mass index (BMI) is a metric widely used to measure the healthy weight of an individual and to predict a person’s risk of developing serious illnesses. Study the statistical association between genetically transmitted traits and BMI might be of interest. Objectives. The present study designed to extend the inadequate evidence concerning the influence of some genetically transmitted traits including ABO blood type, Rh factor, eye color, and hair color on BMI variation. Methods. A total of 142 undergraduate female students of the Department of Clinical Laboratory Sciences, Faculty of Applied Medical Sciences, King Khalid University, Abha, Saudi Arabia, were participated to investigate the possible linkage between genetic traits and BMI variations. Height and weight are collected from participants for BMI measurement. ABO blood type and Rh factor were determined by antisera. Results. Out of 142 female students, 48 were categorized in the first tertile (T1: less than 19.8 kg/m2), 50 were categorized in the second tertile (T2: between 19.8 and 23.7 kg/m2), and 44 were categorized in the third tertile (T3: greater than 23.7 kg/m2). Chi-square analysis shows that there were no associations of genetic traits including hair color, eye color, ABO blood type, and Rh blood type with BMI. However, a significant association between hair color and BMI was observed using multinomial logistic regression analysis. Conclusions. Our data provides a more robust prediction of the relative influence of genetic effects such as hair color on BMI. Future studies may contribute to identifying more association between genes involved in hair pigmentation and BMI variation.

scholarly journals ABO blood type and risk of porcine bioprosthetic aortic valve degeneration: SWEDEHEART observational cohort study

BMJ Open ◽  
2019 ◽  
Vol 9 (5) ◽  
pp. e029109 ◽  
Author(s):  
Michael Persson ◽  
Gustaf Edgren ◽  
Magnus Dalén ◽  
Natalie Glaser ◽  
Martin L Olsson ◽  
...  
Keyword(s):  
Heart Failure ◽  
Cohort Study ◽  
Aortic Valve ◽  
Aortic Valve Replacement ◽  
Valve Replacement ◽  
Type A ◽  
Blood Type ◽  
Type B ◽  
Structural Valve Deterioration ◽  
Abo Blood Type

ObjectiveBlood type A antigen on porcine aortic bioprostheses might initiate an immune reaction leading to an increased frequency of structural valve deterioration in patients with blood type B or O. The aim was to analyse the association between ABO blood type and porcine bioprosthetic aortic valve degeneration.DesignObservational nationwide cohort study.SettingSwedish population-based study.ParticipantsAdult patients (n=3417) who underwent surgical aortic valve replacement and received porcine bioprosthetic aortic valves between 1995 and 2012 from the Swedish Web system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies register. The study database was enriched with information from other national registers.ExposureThe patients were categorised into type A/AB and type B/O blood groups.Primary and secondary outcome measuresPrimary outcome measure was aortic valve reoperation, and secondary outcomes were heart failure and all-cause mortality. We report risk estimates that account for the competing risk of death.ResultsIn total, 3417 patients were identified: 1724 (50.5%) with blood type A/AB and 1693 (49.5%) with blood type B/O. Both groups had similar baseline characteristics. The cumulative incidence of aortic valve reoperation was 3.4% (95% CI 2.5% to 4.4%) and 3.6% (95% CI 2.6% to 4.6%) in the type B/O and the A/AB group, respectively, at 15 years of follow-up (absolute risk difference: −0.2% (95% CI −1.5% to 1.2%)). There was no significantly increased risk for aortic valve reoperation in patients with blood type B/O compared with type A/AB (HR 0.95, 95% CI 0.62 to 1.45). There was no significant difference in absolute or relative risk of heart failure or death between the groups.ConclusionsWe found no significant association between patient blood type and clinical manifestations of structural valve deterioration following porcine aortic valve replacement. Our findings suggest that it is safe to use porcine bioprosthetic valves without consideration of ABO blood type in the recipient.Trial registration numberNCT02276950

The Impact of Blood Type O on Major Outcomes in Patients With Severe Burns

2020 ◽  
Vol 41 (5) ◽  
pp. 1111-1117 ◽  
Author(s):  
Renqi Yao ◽  
Wenjia Hou ◽  
Tuo Shen ◽  
Shuo Zhao ◽  
Xingfeng He ◽  
...  
Keyword(s):  
Hospital Mortality ◽  
Clinical Outcomes ◽  
Poor Prognosis ◽  
Kidney Injury ◽  
Blood Type ◽  
Blood Types ◽  
Severe Burns ◽  
Icu Length Of Stay ◽  
Abo Blood Type ◽  
The Impact

Abstract ABO blood type has been reported to be a predictor of poor prognosis in critically ill patients. Here, we aim to correlate different blood types with clinical outcomes in patients with severe burns. We conducted a single-center retrospective cohort study by enrolling patients with severe burn injuries (≥40% TBSA) between January 2012 and December 2017. Baseline characteristics and clinical outcomes were compared between disparate ABO blood types (type O vs non-O type). Multivariate logistic and linear regression analyses were performed to identify an association between ABO blood type and clinical outcomes, including in-hospital mortality, the development of acute kidney injury (AKI), and hospital or ICU length of stay. A total of 141 patients were finally enrolled in the current study. Mortality was significantly higher in patients with type O blood compared with those of other blood types. The development of AKI was significantly higher in patients with blood type O vs non-O blood type (P = .001). Multivariate analysis demonstrated that blood type O was independently associated with in-hospital mortality and AKI occurrence after adjusting for other potential confounders. Our findings indicated the blood type O was an independent risk factor of both increased mortality and the development of AKI postburn. More prudent and specific treatments are required in treating these patients to avoid poor prognosis.

Maternal ABO Blood Type and Factors Associated With Preeclampsia Subtype

2019 ◽  
Vol 21 (3) ◽  
pp. 264-271 ◽  
Author(s):  
Adriane Burgess ◽  
Teresa S. Johnson ◽  
Amanda Simanek ◽  
Theodore Bell ◽  
Sandra Founds
Keyword(s):  
Early Onset ◽  
Late Onset ◽  
Risk Identification ◽  
Blood Type ◽  
Tertiary Referral Center ◽  
South Central ◽  
Central Pennsylvania ◽  
Subtype Identification ◽  
Abo Blood Type ◽  
Early Onset Preeclampsia

Background: The pathophysiology of preeclampsia remains unclear. The disorder is heterogeneous, and the pathophysiology may vary by subtype. Identification of relevant biomarkers will help to better elucidate the pathophysiologic basis of each preeclampsia subtype. Blood type may be a biomarker that allows risk identification for preeclampsia. Objective: The purpose of this study was to investigate the associations among maternal ABO blood type and preeclampsia subtype and fetal growth restriction (FGR). Method: Medical records of 126 women with early-onset preeclampsia (≤33 6/7 weeks’ gestation), 126 women with late-onset preeclampsia (≥34 0/7 weeks’ gestation), and 259 controls who gave birth between January 2012 and June 2016 were retrospectively abstracted from a large suburban tertiary referral center in South Central Pennsylvania for this hospital-based case–control study. Results: Women with AB blood type had >3 times the odds of late-onset preeclampsia (odds ratio [ OR] = 3.35, 95% confidence interval (CI) = [1.02, 11.05]) compared to those with O blood type. Among women with early-onset preeclampsia, those with B blood type had 5 times the odds of having a growth-restricted fetus than did women with O blood type ( OR = 5.44, 95% CI [1.65, 17.94]). Discussion: Our findings suggest that AB blood type may be an important risk factor for late-onset preeclampsia and that among women with early-onset preeclampsia, those with B blood type have increased odds of FGR. These findings warrant further study in women and their offspring to identify the pathophysiologic processes that may link ABO blood type, preeclampsia subtype, and FGR.

scholarly journals Aging and ABO blood type influence von Willebrand factor and factor VIII levels through interrelated mechanisms

2016 ◽  
Vol 14 (5) ◽  
pp. 953-963 ◽  
Author(s):  
S. Albánez ◽  
K. Ogiwara ◽  
A. Michels ◽  
W. Hopman ◽  
J. Grabell ◽  
...  
Keyword(s):  
Factor Viii ◽  
Von Willebrand Factor ◽  
Blood Type ◽  
Abo Blood Type ◽  
Von Willebrand ◽  
Willebrand Factor

Abstract 1293: ABO blood type and cancer risk: preliminary findings from a phenome analysis

2017 ◽  
Author(s):  
Alicia Beeghly-Fadiel ◽  
Ayush Giri ◽  
Lisa Bastarache ◽  
Jill Pulley ◽  
Jeremy Warner ◽  
...  
Keyword(s):  
Cancer Risk ◽  
Blood Type ◽  
Abo Blood Type
Sign in / Sign up

Export Citation Format

Share Document